Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Employees - 3100,
CEO - Mr. Kim Kelderman,
Sector - Healthcare,
Country - US,
Market Cap - 8.67B
Altman ZScore(max is 10): 10.3, Piotroski Score(max is 10): 7, Working Capital: $473384000, Total Assets: $2670424000, Retained Earnings: $0, EBIT: 231472000, Total Liabilities: $591932000, Revenue: $1196015000
AryaFin Target Price - $37.29 - Current Price $54.86 - Analyst Target Price $83.58
| Ticker | TECH |
| Index | S&P 500 |
| Curent Price | 54.86 |
| Change | -6.03% |
| Market Cap | 8.67B |
| Average Volume | 1.60M |
| Income | 158.11M |
| Sales | 1.20B |
| Book Value/Share | 13.16 |
| Cash/Share | 1.12 |
| Dividend Est | 0.26 (0.47%) |
| Dividend TTM | 0.32 (0.58%) |
| Dividend Ex-Date | Feb 14, 2025 |
| Employees | 3100 |
| Moving Avg 20days | -8.84% |
| Moving Avg 50days | -15.81% |
| Moving Avg 200days | -23.84% |
| Shares Outstanding | 157.92M |
| Earnings Date | Feb 05 BMO |
| Inst. Ownership | 100.12% |
| Price/Earnings | 55.76 |
| Forwad P/E | 24.97 |
| PE Growth | 4.30 |
| Price/Sales | 7.25 |
| Price/Book | 4.17 |
| Price/Cash | 48.85 |
| Price/FCF | 34.10 |
| Quick Ratio | 2.77 |
| Current Ratio | 3.94 |
| Debt/Equity | 0.19 |
| Return on Assets | 5.85% |
| Return on Equity | 7.82% |
| Return on Investment | 6.43% |
| Gross Margin | 66.44% |
| Ops Margin | 21.42% |
| Profit Margin | 13.22% |
| RSI | 29.90 |
| BETA(β) | 1.44 |
| From 52week Low | -3.07% |
| From 52week High | -35.89% |
| EPS | 0.98 |
| EPS next Year | 2.20 |
| EPS next Qtr | 0.51 |
| EPS this Year | 7.10% |
| EPS next 5 Year | 12.96% |
| EPS past 5 Year | 11.13% |
| Sales past 5 Year | 10.61% |
| EPS Y/Y | -29.62% |
| Sales Y/Y | 4.46% |
| EPS Q/Q | 26.57% |
| Sales Q/Q | 8.96% |
| Sales Surprise | 3.94% |
| EPS Surprise | 8.75% |
| ATR(14) | 2.30 |
| Perf Week | -8.49% |
| Perf Month | -11.80% |
| Perf Quarter | -23.84% |
| Perf Year | -20.22% |
| Perf YTD | -23.84% |
| Target Price | 83.58 |
AryaFin Engine© - An AI FinTech Venture - 2024-25 Disclaimer